atezolizumab

Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells.

Atezolizumab-MMAE is an anti-PD-L1 antibody-drug conjugate (ADC) with an EC50 of 1.1 nM. It consists of a humanized anti-PD-L1 antibody (Atezolizumab), a lysosome-cleavable dipeptide linker (valine-citrulline), and a tubulin inhibitor (MMAE), with the drug-linker conjugate being VcMMAE. This ADC exhibits potent cytotoxicity (EC50: 9.75-11.94 nM) and immune activation effects. In the MC38 xenograft humanized PD-1 immune system mouse model, Atezolizumab-MMAE demonstrates significant antitumor activity.

RO7567132 (FAP-LTBR) is a novel bispecific antibody that binds and agonizes LTBR bivalently while binds and antagonizes FAP monovalently, thereby limiting the activation of LTBR to the tumor microenvironment, inducing the formation of local tertiary lymphoid structures (TLS), and reducing systemic toxicity. Its mouse alternative can inhibit breast cancer growth, and the effect is better when combined with atezolizumab. In the mouse colorectal cancer model, it can also enhance immune cell infiltration and TLS-like structure formation.

BXY-14 is a TLR2 agonist and vaccine adjuvant. It significantly downregulates intratumoral PD-L1 expression in mouse models. As a vaccine adjuvant, BXY-14 induces an antibody response. In melanoma mouse models, it shows synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab, potentially extending overall survival. BXY-14 is applicable in melanoma research.

Tiragolumab(MTIG-7192A) is a monoclonal antibody that targets T-cell immunoglobulin and the ITIM structural domain (TIGIT).Tiragolumab is often used in combination with the PD-L1 inhibitor, Atezolizumab, for the treatment of solid malignant tumors such as non-small cell lung cancer.

IMM-20059 is a humanized IgG1 monoclonal antibody targeting EPN1. When combined with Atezolizumab, IMM-20059 significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy.